Shots:
- Median Technologies has received CE Mark for eyonis Lung Cancer Screening (LCS) to detect & diagnose lung cancer
- In testing eyonis LCS has showed 93.3% sensitivity & 92.4% specificity, with 68% reduction of False Positives & 66% reduction of False Negatives, minimizing unnecessary follow-ups
- eyonis Lung Cancer Screening is an AI-powered computer-aided detection & diagnosis (CADe/CADx) Software as a Medical Device (SaMD) that utilizes ML to analyze imaging data from LDCT
Ref: Businesswire | Image: Median Technologies | Press Release
Related News: Median Technologies Receives the US FDA’s 510(k) Clearance for eyonis LCS for Lung Cancer Detection and Diagnosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
